公开(公告)号：EP2563391B1

公开(公告)日：2020-08-26

申请号：EP11716402.0

申请日：2011-04-21

申请人： Roche Glycart AG

发明人： HERTING, Frank ,  KLEIN, Christian

IPC分类号： A61K39/395 ,  A61K31/00

公开(公告)号：EP3434695A1

公开(公告)日：2019-01-30

申请号：EP18187423.1

申请日：2013-08-05

申请人： Roche Glycart AG

发明人： GERDES, Christian ,  KLEIN, Christian ,  NICOLINI, Valeria G. ,  UMANA, Pablo

IPC分类号： C07K16/32 ,  C07K16/28 ,  C07K16/40 ,  C07K16/30 ,  A61P35/00 ,  A61K47/64 ,  A61K47/68

摘要： The present invention provides combinations of (a) an immunoconjugate comprising a first antibody engineered to have reduced effector function and an effector moiety, and (b) a second antibody engineered to have increased effector function, for use in treating a disease in an individual in need thereof. Further provided are pharmaceutical compositions comprising the combinations, and methods of using them.

公开(公告)号：EP2748201B1

公开(公告)日：2017-12-13

申请号：EP12750364.7

申请日：2012-08-21

申请人： Roche Glycart AG

发明人： AST, Oliver ,  BRUENKER, Peter ,  FAUTI, Tanja ,  FREIMOSER-GRUNDSCHOBER, Anne ,  NEUMANN, Christiane ,  KLEIN, Christian ,  MOESSNER, Ekkehard ,  UMANA, Pablo

IPC分类号： C07K16/28 ,  C07K16/30 ,  C07K16/40 ,  C07K16/46

CPC分类号： C07K16/468 ,  C07K16/2809 ,  C07K16/2863 ,  C07K16/3007 ,  C07K16/3053 ,  C07K16/40 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/626 ,  C07K2317/64 ,  C07K2317/66 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/00

公开(公告)号：EP2603530B1

公开(公告)日：2017-11-08

申请号：EP11740932.6

申请日：2011-08-09

申请人： Roche Glycart AG

发明人： BACAC, Marina ,  FREIMOSER-GRUNDSCHOBER, Anne ,  HOSSE, Ralf ,  KLEIN, Christian ,  MOESSNER, Ekkehard ,  NICOLINI, Valeria G. ,  UMANA, Pablo

IPC分类号： C07K16/40

CPC分类号： C07K16/40 ,  A61K47/6871 ,  A61K51/1075 ,  C07K16/30 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/41 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/92

公开(公告)号：EP2904016A1

公开(公告)日：2015-08-12

申请号：EP13773229.3

申请日：2013-10-03

申请人： Roche Glycart AG

发明人： BRUENKER, Peter ,  FAUTI, Tanja ,  JAEGER, Christiane ,  KLEIN, Christian ,  UMAÑA, Pablo

IPC分类号： C07K16/46 ,  C07K16/28 ,  C07K16/30

CPC分类号： C07K16/2809 ,  A61K39/39541 ,  A61K39/39558 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/30 ,  C07K16/3053 ,  C07K16/468 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/52 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/66 ,  C07K2317/75 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/00

摘要： The present invention relates to bispecific antibodies comprising at least two Fab fragments, wherein the first Fab fragment comprises at least one antigen binding site specific for a first antigen; and the second Fab fragment comprises at least one antigen binding site specific for a second antigen, wherein either the variable regions or the constant regions of the second Fab heavy and light chain are exchanged and the two Fab fragments are connected to each other by two peptide linkers; and wherein the bispecific antibody is devoid of a Fc domain; methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

摘要翻译： 本发明涉及包含至少两个Fab片段的双特异性抗体，其中第一Fab片段包含至少一个对第一抗原特异的抗原结合位点; 并且第二Fab片段包含至少一个针对第二抗原特异性的抗原结合位点，其中第二Fab重链和轻链的可变区或恒定区被交换，并且两个Fab片段通过两个肽彼此连接 接头; 并且其中所述双特异性抗体缺乏Fc结构域; 其制备方法，含有所述抗体的药物组合物及其用途。

公开(公告)号：EP2205318B1

公开(公告)日：2014-11-19

申请号：EP08841724.1

申请日：2008-10-22

申请人： Roche Glycart AG

发明人： FERTIG, Georg ,  FRIESS, Thomas ,  KLEIN, Christian ,  UMANA, Pablo

IPC分类号： C07K16/28 ,  A61K39/395 ,  A61P35/00 ,  A61K31/00

CPC分类号： A61K39/39558 ,  A61K31/69 ,  A61K47/00 ,  A61K2039/505 ,  C07K16/2887 ,  C07K2317/24 ,  C07K2317/41 ,  A61K2300/00

公开(公告)号：EP2747781A1

公开(公告)日：2014-07-02

申请号：EP12748490.5

申请日：2012-08-21

申请人： Roche Glycart AG

发明人： BRUENKER, Peter ,  FAUTI, Tanja ,  JAEGER, Christiane ,  KLEIN, Christian ,  UMANA, Pablo

IPC分类号： A61K39/395 ,  A61P35/00 ,  C07K16/30

CPC分类号： C07K16/468 ,  C07K16/2809 ,  C07K16/30 ,  C07K16/3053 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/66

摘要： The present invention relates to bispecific antibodies that specifically bind a T-cell activating antigen and a Tumor Antigen (TA), comprising a first Fab fragment and a second Fab fragment, wherein either the variable regions or the constant regions of the second Fab heavy and light chain are exchanged; and wherein the bispecific antibody does not comprise a Fc domain; methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

摘要翻译： 本发明涉及双特异性抗体也特异性结合T细胞活化抗原和包含第一Fab片段和第二Fab片段肿瘤抗原（TA），worin无论可变区或所述第二Fab重的恒定区和 轻链被交换; 和worin双特异性抗体不包括Fc结构域; 它们的生产方法，药物组合物含有所述抗体，及其用途。

公开(公告)号：EP2673294A1

公开(公告)日：2013-12-18

申请号：EP12702045.1

申请日：2012-02-07

申请人： Roche Glycart AG

发明人： AST, Oliver ,  BRUENKER, Peter ,  FREIMOSER-GRUNDSCHOBER, Anne ,  HERTER, Sylvia ,  HOFER, Thomas U. ,  HOSSE, Ralf ,  KLEIN, Christian ,  MOESSNER, Ekkehard ,  NICOLINI, Valeria G. ,  UMANA, Pablo

IPC分类号： C07K14/55 ,  C12N15/26 ,  A61K39/395 ,  A61K47/48

CPC分类号： C07K16/40 ,  A61K38/2013 ,  A61K47/6813 ,  A61K47/6849 ,  A61K47/6871 ,  A61K47/6891 ,  A61K2039/505 ,  C07K14/55 ,  C07K16/30 ,  C07K2319/00

摘要： The present invention generally relates to mutant interleukin-2 polypeptides that exhibit reduced affinity to the ±-subunit of the IL-2 receptor, for use as immunotherapeutic agents. In addition, the invention relates to immunoconjugates comprising said mutant IL-2 polypeptides, polynucleotide molecules encoding the mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.

公开(公告)号：EP2672999A2

公开(公告)日：2013-12-18

申请号：EP12704250.5

申请日：2012-02-07

申请人： Roche Glycart AG

发明人： GERDES, Christian ,  KLEIN, Christian ,  MOESSNER, Ekkehard ,  NICOLINI, Valeria G. ,  UMANA, Pablo

IPC分类号： A61K47/48 ,  A61K45/06 ,  A61P35/00 ,  C07K19/00

CPC分类号： C07K16/32 ,  A61K38/00 ,  A61K38/2013 ,  A61K45/06 ,  A61K47/6813 ,  C07K14/52 ,  C07K19/00 ,  C07K2319/33 ,  A61K2300/00

摘要： The present invention provides combinations of (a) an immunoconjugate comprising at least one antigen-binding moiety and an effector moiety, and (b) an antibody engineered to have increased effector function, for use in treating a disease in an individual in need thereof. Further provided are pharmaceutical compositions comprising the combinations, and methods of using them.

公开(公告)号：EP3971206A1

公开(公告)日：2022-03-23

申请号：EP21178401.2

申请日：2012-02-07

申请人： Roche Glycart AG

发明人： AST, Oliver ,  BRUENKER, Peter ,  FREIMOSER-GRUNDSCHOBER, Anne ,  HERTER, Sylvia ,  HOFER, Thomas U. ,  HOSSE, Ralf ,  KLEIN, Christian ,  MOESSNER, Ekkehard ,  NICOLINI, Valeria G. ,  UMAÑA, Pablo

IPC分类号： C07K14/55 ,  C12N15/26 ,  A61K39/395 ,  A61K38/20 ,  A61K47/68 ,  A61P37/04 ,  A61P35/00

摘要： The present invention generally relates to mutant interleukin-2 polypeptides that exhibit reduced affinity to the α-subunit of the IL-2 receptor, for use as immunotherapeutic agents. In addition, the invention relates to immunoconjugates comprising said mutant IL-2 polypeptides, polynucleotide molecules encoding the mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.